如何应对抗疟药物耐药性？
How to tackle antimalarial resistance?
机构信息
Medicines for Malaria Venture, Geneva, Switzerland.
出版信息
EMBO Mol Med. 2017 Feb;9(2):133-134. doi: 10.15252/emmm.201607295.
Abstract
In the context of drug resistance, malaria is no exception. Even the latest artemisinins have started to lose their full efficacy in patients. Didier Leroy tells us about the strategies adopted by Medicines for Malaria Venture to reduce this terrible culprit. [Image: see text]
摘要
在耐药性方面，疟疾也不例外。即使是最新的青蒿素类药物，也开始在患者身上失去全部疗效。Didier Leroy 向我们介绍了疟疾药物开发联盟采取的策略，以减少这一可怕的罪魁祸首。[图片：见正文]
相似文献
1
How to tackle antimalarial resistance?如何应对抗疟药物耐药性？
EMBO Mol Med. 2017 Feb;9(2):133-134. doi: 10.15252/emmm.201607295.
2
Drug-resistant malaria advances in Mekong.耐药疟疾在湄公河流域蔓延。
Science. 2017 Oct 13;358(6360):155-156. doi: 10.1126/science.358.6360.155.
3
Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India.印度东部出现对青蒿素耐药的恶性疟原虫疟疾的证据。
N Engl J Med. 2018 Nov 15;379(20):1962-1964. doi: 10.1056/NEJMc1713777.
4
Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.柬埔寨三突变（包括kelch13 C580Y）导致双氢青蒿素-哌喹耐药：一项观察性队列研究。
Lancet Infect Dis. 2015 Jun;15(6):683-91. doi: 10.1016/S1473-3099(15)70049-6. Epub 2015 Apr 12.
5
Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam.单一多重耐药疟原虫谱系（PfPailin）传播至越南。
Lancet Infect Dis. 2017 Oct;17(10):1022-1023. doi: 10.1016/S1473-3099(17)30524-8.
6
Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa.非洲出现对青蒿素耐药的恶性疟原虫。
N Engl J Med. 2017 Mar 9;376(10):991-3. doi: 10.1056/NEJMc1612765. Epub 2017 Feb 22.
7
Back on TRAC: New trial launched in bid to outpace multidrug-resistant malaria.回归追踪：为战胜耐多药疟疾启动新试验。
Nat Med. 2016 Mar;22(3):220-1. doi: 10.1038/nm0316-220.
8
High Antimalarial Efficacy of Dihydroartemisinin-Piperaquine on the China-Myanmar Border: The Calm Before the Storm.双氢青蒿素-哌喹在中国-缅甸边境的高抗疟疗效：暴风雨前的平静。
Am J Trop Med Hyg. 2015 Sep;93(3):436-437. doi: 10.4269/ajtmh.15-0349. Epub 2015 Aug 17.
9
A brief history of artemisinin: Modes of action and mechanisms of resistance.青蒿素的简史：作用模式和耐药机制。
Chin J Nat Med. 2019 May 20;17(5):331-336. doi: 10.1016/S1875-5364(19)30038-X.
10
Skirmishing over the scope of the threat.就威胁的范围展开小规模冲突。
Science. 2016 Apr 22;352(6284):403. doi: 10.1126/science.352.6284.403. Epub 2016 Apr 21.
引用本文的文献
1
Grasp of dihydroartemisinin resistance in Indonesia: Focused on genetic polymorphisms and new antimalarial.印度尼西亚对双氢青蒿素耐药性的掌握：聚焦于基因多态性与新型抗疟药
Narra J. 2023 Dec;3(3):e336. doi: 10.52225/narra.v3i3.336. Epub 2023 Dec 11.
2
Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline.乌干达疟原虫分离株对抗疟药物研发管线的敏感性。
Microbiol Spectr. 2023 Jun 15;11(3):e0523622. doi: 10.1128/spectrum.05236-22. Epub 2023 May 9.
3
Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance.双药效团阿替唑米劫持疟原虫泛素蛋白酶体系统以杀死疟原虫，同时克服耐药性。
Cell Chem Biol. 2023 May 18;30(5):457-469.e11. doi: 10.1016/j.chembiol.2023.04.006. Epub 2023 May 5.
4
Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials.评估恶性疟原虫对选择下一代抗疟药物的耐药风险。
Trends Parasitol. 2021 Aug;37(8):709-721. doi: 10.1016/j.pt.2021.04.006. Epub 2021 May 14.
5
MalDA, Accelerating Malaria Drug Discovery.疟疾药物研发加速计划（Malaria Drug Discovery Accelerator，简称 MalDA）
Trends Parasitol. 2021 Jun;37(6):493-507. doi: 10.1016/j.pt.2021.01.009. Epub 2021 Feb 26.
6
Amodiaquine resistance in is associated with His95Pro mutation, loss of chloroquine, artemisinin and primaquine sensitivity, and high transcript levels of key transporters.[具体病原体名称]中的阿莫地喹耐药性与His95Pro突变、氯喹、青蒿素和伯氨喹敏感性丧失以及关键转运蛋白的高转录水平有关。
Wellcome Open Res. 2017 Jun 20;2:44. doi: 10.12688/wellcomeopenres.11768.2. eCollection 2017.
7
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.抗疟药物耐药性：将恶性疟原虫生物学与临床联系起来
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
8
K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness .K13突变对臭氧敏感性和寄生虫适应性有不同影响。
mBio. 2017 Apr 11;8(2):e00172-17. doi: 10.1128/mBio.00172-17.
本文引用的文献
1
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.耐哌喹恶性疟原虫疟疾的替代标志物：一项表型-基因型关联研究。
Lancet Infect Dis. 2017 Feb;17(2):174-183. doi: 10.1016/S1473-3099(16)30415-7. Epub 2016 Nov 3.
2
Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study.柬埔寨恶性疟原虫疟疾中与双氢青蒿素-哌喹治疗失败相关的遗传标记：一项基因型-表型关联研究。
Lancet Infect Dis. 2017 Feb;17(2):164-173. doi: 10.1016/S1473-3099(16)30409-1. Epub 2016 Nov 3.
3
Artemisinin Action and Resistance in Plasmodium falciparum.青蒿素在恶性疟原虫中的作用与耐药性
Trends Parasitol. 2016 Sep;32(9):682-696. doi: 10.1016/j.pt.2016.05.010. Epub 2016 Jun 9.
4
Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.mTOR激酶耐药性突变非守门人热点的鉴定
Cell Rep. 2015 Apr 21;11(3):446-59. doi: 10.1016/j.celrep.2015.03.040. Epub 2015 Apr 9.
5
The effects of chromatin organization on variation in mutation rates in the genome.染色质组织对基因组突变率变异的影响。
Nat Rev Genet. 2015 Apr;16(4):213-23. doi: 10.1038/nrg3890. Epub 2015 Mar 3.
6
Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.青蒿素类抗疟药作用机制的思考：第1部分——“碳自由基”和“血红素”假说
Infect Disord Drug Targets. 2013 Aug;13(4):217-77. doi: 10.2174/1871526513666131129155708.
7
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
Zotero 插件